Literature DB >> 19803535

New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?

Stavros Apostolakis1, Eduard Shantsila, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19803535     DOI： 10.2165/11313780-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

Review 1.  Novel oral anticoagulants.

Authors:  C W Khoo; K-H Tay; E Shantsila; G Y H Lip
Journal:  Int J Clin Pract       Date:  2009-02-16       Impact factor: 2.503

2.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

3.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

4.  Monitoring direct thrombin inhibitors with a plasma diluted thrombin time.

Authors:  Jason E Love; Chris Ferrell; Wayne L Chandler
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

5.  Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

Authors:  Sorrel E Wolowacz; Neil S Roskell; Jonathan M Plumb; Joseph A Caprini; Bengt I Eriksson
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

Review 6.  American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?

Authors:  John W Eikelboom; Ganesan Karthikeyan; Nick Fagel; Jack Hirsh
Journal:  Chest       Date:  2009-02       Impact factor: 9.410

Review 7.  Brave new world: the current and future use of novel anticoagulants.

Authors:  Alex C Spyropoulos
Journal:  Thromb Res       Date:  2008-10-02       Impact factor: 3.944

8.  A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

Authors:  Laura McCullagh; Lesley Tilson; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Authors:  Alexander G G Turpie; Michael R Lassen; Bruce L Davidson; Kenneth A Bauer; Michael Gent; Louis M Kwong; Fred D Cushner; Paul A Lotke; Scott D Berkowitz; Tiemo J Bandel; Alice Benson; Frank Misselwitz; William D Fisher
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321

10.  Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.

Authors:  William D Fisher; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; Michael Gent; Sylvia Haas; Martin Homering; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Journal:  Thromb Haemost       Date:  2007-06       Impact factor: 5.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.